OncoMultiDx
OncoMultiDx
Multiplex Rapid Test for Multi-Cancer Screening in a Single Assay
Overview:
OncoMultiDx is OncoFirm Diagnostics’ most advanced lateral flow assay, designed to detect multiple cancer types from a single sample—providing a comprehensive, rapid, and non-invasive cancer screening tool for clinical environments. Utilizing a proprietary combination of TF and Gal-GalNAc antigens, along with enhanced nanoparticle signal amplification and multiplexing technology, OncoMultiDx delivers powerful diagnostic insights in less than 15 minutes.
Key Features:
- Multi-Cancer Detection: Screens for multiple high-incidence cancers, including breast, colorectal, pancreatic, ovarian, and lung.
- Single-Sample Efficiency: Performs simultaneous biomarker analysis using blood, serum, or plasma, reducing time and resource demands.
- Multiplexing Technology: Each test strip includes distinct detection zones for individual cancer types.
- Digital Integration: Smartphone-enabled interpretation for enhanced reporting, tracking, and EHR connectivity.
- Point-of-Care Ready: Requires no specialized lab equipment—ideal for use in hospitals, clinics, and mobile screening programs.
Clinical Applications:
- General population screening in primary care and preventive health programs
- Early detection in high-risk individuals or those with genetic predispositions
- Supplemental tool for oncology clinics and diagnostic labs
- Large-scale deployment in government or employer-based cancer screening initiatives
Benefits for Medical Institutions:
- Maximizes diagnostic reach with a single, cost-effective test
- Speeds up early detection and streamlines referral workflows
- Supports data-driven decisions in cancer prevention and treatment planning
- Reduces testing burden on patients and clinicians
Regulatory Status:
OncoMultiDx is currently in advanced stages of clinical validation and will be launched under CE marking in select global markets, with FDA regulatory pathways planed this year.
